Immunotherapy has emerged as one of the most promising avenues in the treatment of cancer, leveraging the body's immune system to fight malignancies. Among the various forms of immunotherapy, cytokine-induced killer (CIK) cell therapy has shown considerable promise due to its unique characteristics. These cells possess both T-cell and natural killer (NK) cell properties, offering potent, broad-spectrum anti-tumor effects.